We discover and develop therapeutics for conventionally undruggable targets using functional selection to target currently inaccessible mechanisms of action.

Using genetically engineered circuits, our platform technologies rely on functional intracellular drug selection as opposed to in vitro screening. This allows us to discover compounds with novel modes of action that can modulate protein interactions in orthosteric or allosteric ways.
 
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover molecular glue-based functional protein degraders using a pre-specified E3 ligase and a neosubstrate of interest.

Our platforms can use canonical small molecule HTS approaches or select from our proprietary genetically encoded peptide and rigidified scaffold libraries of billions of compounds.

Our internal programs are focused on oncology. We select drug targets based on oncogene addiction and synthetic lethality and target them in orthogonal ways.
 

Robert Williamson

Senior Advisor

Tomi Sawyer, PhD

Imagine. Design. Build. Create.

​

Are you an enthusiastic scientist who wants to bring therapies into the clinic? Do you want to use synthetic biology to advance drug discovery? We are always keeping an eye out for new talented members to join our growing team.

​

RESEARCH ASSISTANTS (BS or MS):

• Molecular Biology

• Biochemistry

• Cell Biology

• Peptide Chemistry

​

​

RESEARCH SCIENTISTS (PhD+):

• Proteomics

• Enzyme Engineering

• Microbial Genetics

• Biochemistry

• Cancer Cell Biology